[go: up one dir, main page]

MX2012010935A - Formulacion acuosa estable mejorada de (e)-4-carboxiestiril-4-clor obencil sulfona. - Google Patents

Formulacion acuosa estable mejorada de (e)-4-carboxiestiril-4-clor obencil sulfona.

Info

Publication number
MX2012010935A
MX2012010935A MX2012010935A MX2012010935A MX2012010935A MX 2012010935 A MX2012010935 A MX 2012010935A MX 2012010935 A MX2012010935 A MX 2012010935A MX 2012010935 A MX2012010935 A MX 2012010935A MX 2012010935 A MX2012010935 A MX 2012010935A
Authority
MX
Mexico
Prior art keywords
sulfone
carboxystyryl
aqueous formulation
stable aqueous
improved stable
Prior art date
Application number
MX2012010935A
Other languages
English (en)
Inventor
Manoj Maniar
Original Assignee
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconova Therapeutics Inc filed Critical Onconova Therapeutics Inc
Publication of MX2012010935A publication Critical patent/MX2012010935A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe una composición en solución farmacéutica acuosa que comprende entre alrededor de 20 mg/ml a alrededor de 100 mg/ml de por lo menos una aril sulfona a, ß-insaturada radioprotectora y por lo menos un cosolvente que comprende polietilenglicol (PEG), propilenglicol, poliglicerol, DMA, propilenglicol, glicerol, etanol, sorbitol, alcohol isopropílico o una combinación de los mismos en una cantidad de entre alrededor de 25% y alrededor de 90% en peso/volumen y por lo menos un agente estabilizante que comprende un derivado de vitamina E soluble en agua, en donde la composición tiene un pH en intervalo de alrededor de 7.0 a alrededor de 9.5.
MX2012010935A 2010-03-26 2011-03-24 Formulacion acuosa estable mejorada de (e)-4-carboxiestiril-4-clor obencil sulfona. MX2012010935A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31810010P 2010-03-26 2010-03-26
PCT/US2011/029840 WO2011119863A1 (en) 2010-03-26 2011-03-24 Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone

Publications (1)

Publication Number Publication Date
MX2012010935A true MX2012010935A (es) 2012-12-10

Family

ID=44673627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010935A MX2012010935A (es) 2010-03-26 2011-03-24 Formulacion acuosa estable mejorada de (e)-4-carboxiestiril-4-clor obencil sulfona.

Country Status (16)

Country Link
US (2) US9060967B2 (es)
EP (1) EP2552199B1 (es)
JP (1) JP5837919B2 (es)
KR (1) KR101838764B1 (es)
CN (1) CN102821605B (es)
AU (1) AU2011232341B2 (es)
CA (1) CA2792913C (es)
EA (1) EA023535B9 (es)
ES (1) ES2546672T3 (es)
HR (1) HRP20150918T1 (es)
HU (1) HUE027711T2 (es)
IL (1) IL221780A (es)
MX (1) MX2012010935A (es)
PL (1) PL2552199T3 (es)
SI (1) SI2552199T1 (es)
WO (1) WO2011119863A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014079020A1 (en) * 2012-11-22 2014-05-30 Original Biomedicals Co., Ltd. Pharmaceutical composition used for reducing damage caused by free radicals
CN105997878B (zh) * 2012-11-22 2019-03-22 原创生医股份有限公司 降低自由基伤害的复合微胞载体医药组成物
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
EP3691620B1 (en) 2017-10-05 2022-07-27 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP4640207A1 (en) * 2022-12-23 2025-10-29 Resonac Corporation Aqueous composition and external preparation for skin
CN117599033B (zh) * 2023-10-25 2024-06-28 华南师范大学 一种抗皮肤老化制剂及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6767926B1 (en) 1999-10-12 2004-07-27 Temple University - Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6673373B2 (en) * 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
ATE406881T1 (de) 2001-02-28 2008-09-15 Univ Temple Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung
WO2004110380A2 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2005065074A2 (en) * 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
WO2005044181A2 (en) * 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
AU2005265412B2 (en) * 2004-07-19 2010-09-02 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones
US20060287301A1 (en) * 2005-06-17 2006-12-21 Mcnair Douglas Novel formulations for phenothiazines, including fluphenazine and its derivatives
JP5107246B2 (ja) 2005-07-29 2012-12-26 オンコノバ・セラピューティックス・インコーポレーテッド 放射線防護α，β−不飽和アリールスルホンの製剤
KR101156325B1 (ko) 2006-07-28 2012-07-10 온코노바 테라퓨틱스, 인코포레이티드 방사선 보호 α,β 불포화 아릴설폰 제형
WO2008088803A2 (en) 2007-01-16 2008-07-24 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones
CN101787118B (zh) * 2010-03-10 2011-09-14 浙江大学 无溶剂合成水溶性维生素e聚乙二醇琥珀酸酯的方法
EP2549867A4 (en) * 2010-03-24 2013-08-14 Onconova Therapeutics Inc COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING WOUNDS

Also Published As

Publication number Publication date
EP2552199B1 (en) 2015-06-03
JP2013523649A (ja) 2013-06-17
EP2552199A4 (en) 2013-08-07
HUE027711T2 (en) 2016-11-28
US20130012589A1 (en) 2013-01-10
ES2546672T3 (es) 2015-09-25
WO2011119863A1 (en) 2011-09-29
US9060967B2 (en) 2015-06-23
EA201270745A1 (ru) 2013-02-28
CA2792913A1 (en) 2011-09-29
SI2552199T1 (sl) 2015-10-30
EA023535B1 (ru) 2016-06-30
CN102821605B (zh) 2015-11-25
JP5837919B2 (ja) 2015-12-24
CN102821605A (zh) 2012-12-12
EA023535B9 (ru) 2016-11-30
HRP20150918T1 (hr) 2016-01-29
KR101838764B1 (ko) 2018-03-14
US20150265549A1 (en) 2015-09-24
PL2552199T3 (pl) 2015-11-30
IL221780A (en) 2017-03-30
AU2011232341A1 (en) 2012-10-04
CA2792913C (en) 2020-01-21
AU2011232341B2 (en) 2014-05-01
EP2552199A1 (en) 2013-02-06
US9713597B2 (en) 2017-07-25
KR20130103650A (ko) 2013-09-24

Similar Documents

Publication Publication Date Title
MX2012010935A (es) Formulacion acuosa estable mejorada de (e)-4-carboxiestiril-4-clor obencil sulfona.
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
DOP2012000261A (es) Formulaciones de insulina de accion prolongada
MX2016015636A (es) Formulaciones cannabinoides estables.
ES2720954T3 (es) Formulaciones estabilizadas de estatina
EA201170543A1 (ru) Жидкий фармацевтический состав, содержащий парацетамол
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
HRP20161771T4 (hr) Formulacije bendamustina
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
IN2014MN02213A (es)
MX373040B (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador.
DE502008002872D1 (de) Flüssige formulierungen enthaltend carotinoide
EA200600528A1 (ru) Способ получения водорастворимых дитерпенов и их применение
AR034370A1 (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
UY38055A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario
AR077347A1 (es) Mejoramientos en composiciones farmaceuticas y relacionados con ellas
AR058323A1 (es) Formulacion de suspension de fexofenadina
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
ITMI20022549A1 (it) Composizione quaternaria comprendente come sostanza attiva la propolis.
BRPI0511387A (pt) composição e seu uso
BRPI0607990A2 (pt) formulação de um aerossol farmacêutico para inaladores dosimetrados pressurizados contendo um agente seqüestrante, uso do agente sequestrante, inalador de dosimetrado pressurizado e método de preenchimento do inalador de aerossol

Legal Events

Date Code Title Description
FG Grant or registration